Expertise in
25
conditions

Dr. David L. Grisell

Radiation Oncology
GHS Cancer Institute
900 W Faris Rd, 
Greenville, SC 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
25
conditions
GHS Cancer Institute
900 W Faris Rd, 
Greenville, SC 

Overview

David Grisell is a Radiation Oncologist practicing medicine in Greenville, South Carolina.

Dr. Grisell is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Acoustic Neuroma, Posterior Fossa Tumor, Astrocytoma, and Alveolar Soft Part Sarcoma.

He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 17 clinical trials.

Specialties

Radiation Oncology

Licenses

Radiology in SC

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D

Locations

GHS Cancer Institute
900 W Faris Rd, Greenville, SC 29605

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Enrollment Status: Recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Other, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Enrollment Status: Recruiting
Publish Date: June 25, 2026
Intervention Type: Other, Procedure, Radiation
Study Phase: Phase 3
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug
Study Drug: Temozolomide
Study Phase: Phase 2
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Radiation
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
Enrollment Status: Completed
Publish Date: July 09, 2026
Intervention Type: Other, Radiation
Study Phase: Phase 3
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Enrollment Status: Completed
Publish Date: June 17, 2026
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Doxorubicin, Ifosfamide, Pazopanib
Study Phase: Phase 2/Phase 3
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Enrollment Status: Completed
Publish Date: May 22, 2026
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Enrollment Status: Terminated
Publish Date: May 22, 2026
Intervention Type: Radiation
Study Phase: Phase 2
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
Enrollment Status: Completed
Publish Date: February 23, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Chemotherapy, Erlotinib hydrochloride, Fluorouracil, Gemcitabine hydrochloride
Study Phase: Phase 3
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug, Radiation
Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine
Study Phase: Phase 3
View 8 Less Clinical Trials

3 Total Publications

Significance of Co-expression of Epidermal Growth Factor Receptor and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiotherapy: An Analysis of NRG Oncology RTOG 9811.
Significance of Co-expression of Epidermal Growth Factor Receptor and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiotherapy: An Analysis of NRG Oncology RTOG 9811.
Journal: International journal of radiation oncology, biology, physics
Published: July 21, 2016
Similar Doctors
Expertise in
19
conditions
Dr. Michael P. Greenbaum
Radiation Oncology
Expertise in
19
conditions
Dr. Michael P. Greenbaum
Radiation Oncology
Referral may be required
Before you request

Prisma Health Cancer Institute – Faris Rd.

900 West Faris Road, 
Greenville, SC 
 (0.1 miles away)
864-679-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Greenbaum is a Radiation Oncologist practicing medicine in Greenville, South Carolina. Dr. Greenbaum is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Lung Cancer, Small Cell Lung Cancer (SCLC), and Posterior Fossa Tumor. Dr. Greenbaum is board certified in American Board Of Radiology. Dr. Greenbaum is currently accepting new patients.

Expertise in
24
conditions
Dr. Shirnett M. Matthews
Radiation Oncology
Expertise in
24
conditions
Dr. Shirnett M. Matthews
Radiation Oncology
Referral may be required
Before you request

Prisma Health Cancer Institute – Faris Rd.

900 West Faris Road, 
Greenville, SC 
 (0.1 miles away)
864-679-3900
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Shirnett Matthews is a Radiation Oncologist practicing medicine in Greenville, South Carolina. Dr. Matthews is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Vulvar Cancer, Pleuropulmonary Blastoma, Lung Cancer, and Small Cell Lung Cancer (SCLC). Dr. Matthews is board certified in American Board Of Radiology. Dr. Matthews is currently accepting new patients.

Expertise in
27
conditions
Dr. John J. O'connell
Radiation Oncology
Expertise in
27
conditions
Dr. John J. O'connell
Radiation Oncology
Referral may be required
Before you request

Prisma Health Cancer Institute Multidisciplinary Center – Faris Rd.

890 West Faris Road, Suite 320, 
Greenville, SC 
 (0.1 miles away)
864-455-1200
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John O'connell is a Radiation Oncologist practicing medicine in Greenville, South Carolina. Dr. O'connell is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Posterior Fossa Tumor, Astrocytoma, Embryonal Tumor with Multilayered Rosettes, and Gliosarcoma. Dr. O'connell is board certified in American Board Of Radiology. Dr. O'connell is currently accepting new patients.

Frequently Asked Questions about Dr. David L. Grisell

How do I make an appointment with Dr. David L. Grisell?

You can book an appointment with Dr. David L. Grisell by calling their office at 864-679-3900. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. David L. Grisell a top-rated expert for Acoustic Neuroma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. David L. Grisell is classified as an Distinguished expert for Acoustic Neuroma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. David L. Grisell specialize in?

While Dr. David L. Grisell is a Radiation Oncology, they have specific expertise in Acoustic Neuroma, Posterior Fossa Tumor, and Astrocytoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. David L. Grisell participate in research or clinical trials?

Yes. Dr. David L. Grisell has published 3 articles and abstracts on conditions like Acoustic Neuroma. You can view a list of Dr. David L. Grisell's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. David L. Grisell accept my insurance?

Dr. David L. Grisell accepts most major insurance plans, including Medicare. We recommend calling the office directly at 864-679-3900 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Grisell's expertise for a condition
ConditionClose
    View All 24 Advanced Conditions
    View All 38 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile